Oblique Therapeutics
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
Oblique Therapeutics > News > Company updates
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact

News

Archive
  • November 2020
  • October 2020
  • September 2020
  • June 2020
  • November 2019
  • October 2019
  • July 2019
  • March 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
Categories
  • Company updates
  • News
18 Nov 2020

Oblique Therapeutics AB, raises 98 MSEK in a private placement investment round.

29 Jun 2020

New Press Release-Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms

11 Jun 2020

New Press Release – Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies

04 Jun 2020

General Meeting 2020

27 Nov 2019

Notice convening the Extraordinary General Meeting on December 6 at 2pm

17 Jul 2019

We are proud to have been recognised by StartUp City Magazine as one of the most promising European Biotech startups in 2019!

28 Mar 2019

We welcome our new owners

07 Mar 2019

New collaboration with Pharma

  • «
  • 1
  • 2
  • »
Oblique Therapeutics

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer.  The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. 

Till toppen

We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies

Approve